Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Diamedica Therapeutics Inc (DMAC)

Diamedica Therapeutics Inc (DMAC)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
6.28 unch (unch) 02/12/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 6.28 unch (unch) 16:00 ET
Quote Overview for Wed, Feb 12th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
6.23
Day High
6.35
Open 6.25
Previous Close 6.28 6.28
Volume 70,400 70,400
Avg Vol 75,790 75,790
Stochastic %K 85.30% 85.30%
Weighted Alpha +105.95 +105.95
5-Day Change +0.25 (+4.15%) +0.25 (+4.15%)
52-Week Range 2.14 - 6.45 2.14 - 6.45
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 268,539
  • Shares Outstanding, K 42,761
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,380 K
  • EBIT $ -24 M
  • EBITDA $ -25 M
  • 60-Month Beta 1.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.69

Options Overview Details

View History
  • Implied Volatility 123.07% ( -20.26%)
  • Historical Volatility 47.06%
  • IV Percentile 62%
  • IV Rank 28.17%
  • IV High 400.64% on 08/06/24
  • IV Low 14.23% on 05/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 32
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 281
  • Open Int (30-Day) 528

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.17
  • Number of Estimates 2
  • High Estimate -0.16
  • Low Estimate -0.18
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -21.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.88 +28.69%
on 01/14/25
Period Open: 5.27
6.45 -2.64%
on 02/10/25
+1.01 (+19.17%)
since 01/10/25
3-Month
3.92 +60.20%
on 11/18/24
Period Open: 4.31
6.45 -2.64%
on 02/10/25
+1.97 (+45.71%)
since 11/12/24
52-Week
2.14 +193.46%
on 06/24/24
Period Open: 3.15
6.45 -2.64%
on 02/10/25
+3.13 (+99.37%)
since 02/12/24

Most Recent Stories

More News
Best Momentum Stocks to Buy for October 14th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 14th:IAMGOLD Corporation IAG: This intermediate gold producer has a Zacks Rank #1 and witnessed...

HIVE : 2.75 (+1.10%)
DMAC : 6.28 (unch)
IAG : 6.61 (+3.61%)
New Strong Buy Stocks for October 14th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:HireQuest, Inc. HQI: This company that provides temporary staffing solutions has seen the Zacks Consensus Estimate for its current...

HIVE : 2.75 (+1.10%)
HQI : 13.20 (+2.96%)
CLPR : 3.90 (-1.52%)
DMAC : 6.28 (unch)
IAG : 6.61 (+3.61%)
Three (3) Stocks Under $10 That Insiders Are Buying 

These small-cap names provide an opportunity that insiders are buying including deep value, growth, new technology, and AI.

DMAC : 6.28 (unch)
ADT : 7.31 (-2.27%)
CMTL : 2.15 (-2.27%)
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today announced the appointment of David...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...

DMAC : 6.28 (unch)
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today...

DMAC : 6.28 (unch)
DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment...

DMAC : 6.28 (unch)
KPTI : 0.5858 (-2.06%)
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...

DMAC : 6.28 (unch)
DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...

DMAC : 6.28 (unch)
DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Provides Update on ReMEDy2 Trial

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment...

DMAC : 6.28 (unch)
DiaMedica Therapeutics to Present at Lake Street’s 6th Annual Best Ideas Growth Conference

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...

DMAC : 6.28 (unch)
DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its second...

DMAC : 6.28 (unch)
DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company’s...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the U.S....

DMAC : 6.28 (unch)
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders...

DMAC : 6.28 (unch)
ONC.TO : 1.11 (+1.83%)
ONCY : 0.7814 (+3.41%)
DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...

DMAC : 6.28 (unch)
DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial Officer

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment...

DMAC : 6.28 (unch)
DiaMedica Therapeutics to Present Research at International Stroke Conference

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access Event

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company...

DMAC : 6.28 (unch)
DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial Results

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...

DMAC : 6.28 (unch)
DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S....

DMAC : 6.28 (unch)
DiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its third...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that late-breaking...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the U.S....

DMAC : 6.28 (unch)
DiaMedica Therapeutics Announces Closing of $30 Million Private Placement

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the closing...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Announces $30 Million Private Placement

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced it has entered...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the initiation...

DMAC : 6.28 (unch)
DiaMedica Therapeutics to Participate at Upcoming Investor Conferences

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company...

DMAC : 6.28 (unch)
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...

DMAC : 6.28 (unch)
HireQuest Reports Financial Results for the Fourth Quarter and Year End 2021

Q4 2021 EPS of $0.16 per Diluted Share, Net Income of $2.2 million, and Adjusted EBITDA of $3.5 million Full Year 2021 EPS of $0.87 per Diluted Share, Net Income of $11.8 million, and Adjusted EBITDA of...

HQI : 13.20 (+2.96%)
HireQuest, Inc. To Hold Fourth Quarter and Year End 2021 Financial Results Conference Call on Tuesday, March 15, 2022

GOOSE CREEK, SC / ACCESSWIRE / March 7, 2022 / HireQuest, Inc. (NASDAQ:HQI), a national franchisor of on-demand, temporary, commercial, and professional staffing services, today announced that it will...

HQI : 13.20 (+2.96%)
HireQuest, Inc. Announces Closing of Northbound Executive Search Acquisition

GOOSE CREEK, SC / ACCESSWIRE / February 28, 2022 / HireQuest, Inc. (Nasdaq:HQI), a national franchisor of on-demand, temporary, and commercial staffing services, today announced that it has completed the...

HQI : 13.20 (+2.96%)
HireQuest, Inc. Announces Closing of The Dubin Group and Dubin Workforce Solutions Acquisition

GOOSE CREEK, SC / ACCESSWIRE / February 22, 2022 / HireQuest, Inc. (NASDAQ:HQI), a national franchisor of on-demand, temporary, and commercial staffing services, today announced that it has completed the...

HQI : 13.20 (+2.96%)
HireQuest, Inc. Declares Quarterly Dividend

GOOSE CREEK, SC / ACCESSWIRE / February 22, 2022 / HireQuest, Inc. (NASDAQ:HQI), a national franchisor of on-demand, temporary, and commercial staffing services, today announced that its Board of Directors...

HQI : 13.20 (+2.96%)
HireQuest, Inc. Announces Acquisition of Northbound Executive Search

HireQuest to Acquire Executive Placement and Short-term Consultant Firm in New York GOOSE CREEK, SC / ACCESSWIRE / January 25, 2022 / HireQuest, Inc. (NASDAQ:HQI), a national franchisor of on-demand, temporary,...

HQI : 13.20 (+2.96%)
HireQuest, Inc. Announces Closing of dmDickason Acquisition

GOOSE CREEK, SC / ACCESSWIRE / January 24, 2022 / HireQuest, Inc. (NASDAQ:HQI), a national franchisor of on-demand, temporary, and commercial staffing services, today announced that it has completed the...

HQI : 13.20 (+2.96%)
HireQuest, Inc. Announces Acquisition of The Dubin Group, Inc. and Dubin Workforce Solutions, Inc.

HireQuest to Acquire Commercial Staffing and Executive Placement Providers in Philadelphia GOOSE CREEK, SC / ACCESSWIRE / January 19, 2022 / HireQuest, Inc. (NASDAQ:HQI), a national franchisor of on-demand,...

HQI : 13.20 (+2.96%)
HireQuest, Inc. Announces Acquisition of dmDickason’s Staffing Division

HireQuest, Inc. (Nasdaq: HQI), a national franchisor of on-demand, temporary, and commercial staffing services, today announced that it has entered into a definitive agreement to acquire the staffing division...

HQI : 13.20 (+2.96%)
HireQuest, Inc. Announces Closing of Dental Power Staffing Acquisition

HireQuest, Inc. (Nasdaq: HQI), a national franchisor of on-demand, temporary, and commercial staffing services, today announced that it has completed the previously disclosed acquisition of the Dental...

HQI : 13.20 (+2.96%)

Business Summary

DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada....

See More

Key Turning Points

3rd Resistance Point 6.46
2nd Resistance Point 6.41
1st Resistance Point 6.34
Last Price 6.28
1st Support Level 6.22
2nd Support Level 6.17
3rd Support Level 6.10

See More

52-Week High 6.45
Last Price 6.28
Fibonacci 61.8% 4.80
Fibonacci 50% 4.30
Fibonacci 38.2% 3.79
52-Week Low 2.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Increase Profitable Opportunities with Barchart's Technical Opinion